A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Latest Information Update: 06 Mar 2024
At a glance
- Drugs PSB 202 (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical; Sound Biologics
- 11 Mar 2022 Status changed from not yet recruiting to recruiting.
- 20 Aug 2021 New trial record